Loading
NEUROONE MEDICAL TECHNOLOGIES Corp Stock: price and insider trades · United States
1 insider bought €57k of shares over the last 90 days, the latest by Wambeke David J., filed 08 Sept 2026.
NEUROONE MEDICAL TECHNOLOGIES Corp: what insiders have been doing
NEUROONE MEDICAL TECHNOLOGIES Corp is a Healthcare & Pharma company. Its directors and officers file their transactions with SEC (Form 4). The last twelve months, up to 22 October 2026, brought 22 filings signed by 9 insiders.
The record shows 2 purchases on the open market worth €625k, made by 1 insider, against 5 sales worth €20k by 1 insider. The net balance comes to €605k on the buying side. Unlike grants, an open-market purchase is paid for by the insider, at the market price. On the buying side, the filings list 1 senior executive among the declarants. One trade stands out by size: a purchase of €568k from Wambeke David J., disclosed on 3 March 2026.
The last purchase on record was published on 8 September 2026, which is 45 days ago. Typically, a trade is published a median of 3 days after it takes place. The legal deadline for a Form 4 is two business days after the transaction. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify.
Across the 3,171 companies tracked on its exchange, the median is 24 filings; at 22 filings, this issuer sits below that mark. The full history, which starts in 2017, counts 11 purchases against 24 sales. For the fiscal year to 30 September 2025, the annual 10-K puts revenue at 9.1 m USD and net income at -3.6 m USD.
Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Insider Decl.
181
Thresholds
n/a
Buy Volume
€951,639
11 ops. · all time
Sell Volume
€629,777
24 ops. · all time
Who traded when
BuySaleChristianson Mark11 sales
David J. Wambeke2 buys
David A. Rosa1 buy
McClurg Ronald W.1 buy
Since the insiders bought
- -40.7%Entry US$1.66 · Close 20 Oct 2026 US$0.98
- +63.6%Entry US$2.64 · Close at T+365 US$4.32
- +63.6%Entry US$2.64 · Close at T+365 US$4.32
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 24,615 of 26,248 companies
17.2
score / 100
Value6
Quality28
FCF yld-33%
Earn yld-40%
EV/EBITDA·
ROE-125%
Gross mgn57%
Net mgn-40%
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended September 2025 · cache
US$0.98
Analyst consensus
3 analysts1.33/5
US$5.00Target US$7.27(+638%)US$8.80
Income statement
RevenueUS$9.1M
Gross profitUS$5.1M57% margin
EBITDA-US$3M-33% margin
Net income-US$3.6M-59.7% margin
Valuation
P/Book2.3x
Beta0.76
Balance sheet & cash
Market capUS$9M
Total debtUS$266.8k
Free Cash Flow-US$2.9M
Debt / Equity5%
Profitability & ownership
ROE-124.7%
ROA-58.1%
% insiders25.4%
% institutions22.0%
Last declaration on 8 September 2026
Declarations181 total
33,333 shares@ US$2.010.54% mcap9.2% of flowCommon StockSEC:0001971798-26-000005:0
Canonical exit: 25 Nov 2026 (T+90)
10,000 shares@ US$3.340.27% mcap14.5% of flowCommonSEC144:0001973097-26-000019
41,929 shares0Common StockSEC:0002103204-26-000005:0
41,929 shares0Common StockSEC:0001656026-26-000003:0
41,929 shares0Common StockSEC:0001215243-26-000004:0
41,929 shares0Common StockSEC:0001296853-26-000001:0
15,363 shares@ US$0.744.9% of flowCommon StockSEC:0001709738-26-000009:0
253 shares@ US$0.7770.1% of flowCommon StockSEC:0001709738-26-000009:1
906 shares@ US$0.7771.5% of flowCommon StockSEC:0001772652-26-000005:0
2,458 shares@ US$0.7770.5% of flowCommon StockSEC:0001540354-26-000005:0
100 shares@ US$0.800.0% of flowCommon StockSEC:0001709738-26-000008:1
817 shares@ US$0.800.3% of flowCommon StockSEC:0001709738-26-000008:0
2,109 shares@ US$0.800.3% of flowCommon StockSEC:0001709738-26-000007:1
11,611 shares@ US$0.804.0% of flowCommon StockSEC:0001709738-26-000007:0
1,000,000 shares@ US$0.670490.8% of flowCommon StockSEC:0001971798-26-000002:0
Canonical exit: 30 May 2026 (T+90)
7,376 shares@ US$0.6810.6% of flowCommon StockSEC:0001772652-26-000004:0
1,812 shares@ US$0.680.5% of flowCommon StockSEC:0001709738-26-000006:0
71,325 shares@ US$0.6812.5% of flowCommon StockSEC:0001540354-26-000004:0
906 shares@ US$0.7581.5% of flowCommon StockSEC:0001772652-26-000001:0
253 shares@ US$0.7580.1% of flowCommon StockSEC:0001709738-26-000001:0
2,458 shares@ US$0.7580.5% of flowCommon StockSEC:0001540354-26-000001:0
7,758 shares0Common StockSEC:0002103204-26-000002:0
906 shares@ US$0.88861.7% of flowCommon StockSEC:0001772652-25-000006:0
253 shares@ US$0.88860.1% of flowCommon StockSEC:0001709738-25-000011:0
2,458 shares@ US$0.88860.6% of flowCommon StockSEC:0001540354-25-000009:0
25 of 181 declarations
About NEUROONE MEDICAL TECHNOLOGIES Corp
NeuroOne Medical Technologies Corporation (ticker: NMTC) is a U.S.-based medical device company listed on the Nasdaq market in the United States. The company focuses on neurotechnology solutions designed to improve the surgical diagnosis and treatment of neurological disorders. Its business sits at the intersection of neurosurgery, electrophysiology, and minimally invasive ablation therapy, which gives it a specialized niche position within the broader medtech landscape. NeuroOne is headquartered in Eden Prairie, Minnesota, a well-established U.S. medical-technology cluster. Although the corporate history traces back to 2009, the company’s current strategic focus was reset after the 2017 acquisition of NeuroOne, Inc., which effectively transformed the business into a dedicated neurological-medtech platform.
NeuroOne’s commercial portfolio is built around a minimally invasive, high-precision technology platform with four FDA-cleared product families under 510(k): Evo Cortical electrodes for surface-brain recording and stimulation, Evo sEEG electrodes for subsurface brain monitoring and stimulation, the OneRF ablation system for radiofrequency lesions in the brain, and the OneRF TN system for pain-related and certain cranial-nerve applications. In operational terms, this gives the company exposure to two adjacent clinical markets: neurological monitoring/diagnostics and therapeutic neuroablation. The strategy is to address medical needs where precision and reduced invasiveness are important, while competing against better-capitalized and more established players in the neuromedical device sector.
Read moreShow less
From a competitive standpoint, NeuroOne aims to differentiate itself through product design rather than scale. Its value proposition is centered on minimally invasive procedures, high-definition signal capture, and targeted lesioning capability. A key commercialization lever is its distribution agreement with Zimmer, which grants Zimmer exclusive distribution rights for certain OneRF products. For a small-cap medtech company, that type of partnership is important because it can broaden market access, support physician adoption, and reduce the burden of building a large direct sales infrastructure from scratch.
Recent developments point to improving commercial traction. In 2025, NeuroOne highlighted strong product revenue growth and reported progress driven by its OneRF platform. It also announced the first successful treatments of facial pain patients using its OneRF trigeminal nerve ablation system. In early 2026, management said momentum had continued across target markets, suggesting that the company is transitioning from a pure development story toward early commercialization. That said, investors should still view NMTC as a high-risk growth story: the company remains exposed to regulatory execution, reimbursement uncertainty, funding needs, and continued Nasdaq listing compliance. For international equity investors, NeuroOne is best characterized as a niche U.S. Nasdaq-listed medtech platform with differentiated technology and still-emerging commercial scale.
